Niloofar Bondariyan

Dr. Niloofar Bondariyan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MVMehrbod Vakhshoori
Mehrbod Vakhshoori
MHMaryam Heidarpour
Maryam Heidarpour
NBNiloofar Bondariyan
Niloofar Bondariyan
NSNiyousha Sadeghpour
Niyousha Sadeghpour
ZMZohreh Mousavi
Zohreh Mousavi
Background. Coronavirus disease 2019 (COVID-19) manifestations varied completely from its time of emergence. However, the assessment of adrenal insufficiency (AI) in this pandemic is lacking. In this review, we aimed to evaluate the status of AI among COVID-19-infected individuals. Methods. A systematic literature screening in PubMed/MEDLINE, Scopus, and Web of Science was performed until May 23, 2021. We collected relevant published peer-reviewed studies that reported AI occurrence in patients who suffered from COVID-19. Results. A total of 10 records (cross-sectional studies: 3, N=256, males: 176 (68.7), and case reports: 7, N=7, males: 4 (57.1)) were recruited. The age spectrum ranged from 22 to 96 years. AI was diagnosed with laboratory assessment or radiologic findings. The AI prevalence ranged from 3.1 to as high as 64.3 in different studies. Except for one patient, all other patients were discharged in stable conditions in published case reports. Conclusion. This review indicates that AI occurrence in the COVID-19 pandemic seems quite probable; however, the extent and type (primary, secondary, and functional) need to be clarified yet. Appropriate early diagnostic and therapeutic interventions should be done, especially in critically ill patients, to prevent lethal outcomes.

13 March 2024 in Tremor and Other Hyperkinetic Movements
Verified
Journal Article
Open access
PDF file
MGMohadese Golsorkhi
Mohadese Golsorkhi
JKJessa Koch
Jessa Koch
FPFarzin Pedouim
Farzin Pedouim
KFKaren Frei
Karen Frei
NBNiloofar Bondariyan
Niloofar Bondariyan
KDKhashayar Dashtipour
Khashayar Dashtipour
Background: Tardive Dyskinesia (TD) is a neurological disorder characterized by involuntary movements, often caused by dopamine receptor antagonists. Vesicular Monoamine Transporter 2 (VMAT2) inhibitors, such as valbenazine and deutetrabenazine, have emerged as promising therapies for TD and several clinical trials have shown their efficacy. This study aims to compare the efficacy and safety profile of VMAT2 inhibitors, focusing on a recent trial conducted in the Asian population. Methods: We reviewed the PubMed, Cochrane Library, Embase database, and clinicaltrials.gov between January 2017 and October 2023, using the keywords “tardive dyskinesia” AND (“valbenazine” [all fields] OR “ deutetrabenazine “ [all fields]) AND “clinical trial”. The reviewed articles were studied for efficacy and side effects. Results: An initial search yielded 230 articles, of which 104 were duplicates. Following the title and abstract screening, 25 additional articles were excluded. A full-text review resulted in the exclusion of 96 more articles. Ultimately, four double-blind clinical trials met the inclusion criteria. The deutetrabenazine studies demonstrated significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores compared to placebo, with no difference in adverse events. The valbenazine studies showed favorable results in reducing TD symptoms and were well-tolerated. Discussion: The studies reviewed in this analysis underscore the potential of deutetrabenazine and valbenazine as valuable treatment options for TD in diverse populations. Both medications demonstrated significant improvements in AIMS scores, suggesting their effectiveness in managing TD symptoms. Additionally, they exhibited favorable safety profiles, with low rates of serious adverse events and no significant increase in QT prolongation, parkinsonism, suicidal ideation, or mortality. Conclusion: The studies reviewed highlight the promising efficacy and tolerability of deutetrabenazine and valbenazine as treatments for Tardive Dyskinesia, providing new hope for individuals affected by this challenging condition.

1 March 2022 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
NBNiloofar Bondariyan
Niloofar Bondariyan
MVMehrbod Vakhshoori
Mehrbod Vakhshoori
NSNiyousha Sadeghpour
Niyousha Sadeghpour
DSdavood shafie
davood shafie
Heart failure,mortality,shock index,age shock index,modified shock index,age-modified shock index,hospital mortality

20 September 2023 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
MVMehrbod Vakhshoori
Mehrbod Vakhshoori
SNSepehr Nemati
Sepehr Nemati
SSSadeq Sabouhi
Sadeq Sabouhi
GTGolchehreh Tavakol
Golchehreh Tavakol
BYBehzad Yavari
Behzad Yavari
DSdavood shafie
davood shafie

16 December 2024 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
NBNiloofar Bondariyan
Niloofar Bondariyan
MGMohadese Golsorkhi
Mohadese Golsorkhi
KDKhashayar Dashtipour
Khashayar Dashtipour
Rotigotine is a dopamine receptor agonist commonly prescribed for Parkinson’s disease (PD) and restless leg syndrome. Although some common side effects have been previously reported, the rotigotine-induced leukoderma is a very rare presentation. Herein, we report a 37-year-old female with PD who developed depigmentation patches after 1 year of rotigotine application. Dermatology consultation reported drug-induced leukoderma, and topical steroid, narrow-band ultraviolet B, and ruxolitinib were administered. Her depigmentation spots started to improve while rotigotine was continued. This case highlights the potential for rotigotine to induce skin depigmentation and emphasizes the need for continued observation and reporting of such adverse effects.

17 August 2026 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
NBNiloofar Bondariyan
Niloofar Bondariyan
MPMilan Patel
Milan Patel
PSPranati Shah
Pranati Shah
DPDaniel Park
Daniel Park
ADAren Dermarderosian
Aren Dermarderosian
MAMojtaba Akhtari
Mojtaba Akhtari
Polycythemia vera (PV) is a clonal myeloproliferative neoplasm primarily caused by the JAK2V617F mutation, present in 95% of patients. It results in erythropoietin-independent hematopoietic proliferation, erythrocytosis, increased hematocrit (Hct), leukocytosis, thrombocytosis, and hyperviscosity, predisposing patients to thrombotic events and neurologic deficits, including erythromelalgia and pruritus. Neurologic manifestations can occur, such as transient ischemic attack (TIA) and stroke. We report an 83-year-old woman, PV patient who presented with chorea and magnetic resonance imaging (MRI) of her brain showed pachymeningeal enhancement (dural-arachnoid enhancement); this radiological finding is most commonly described in intracranial hypotension, autoimmune conditions, infection, and neoplastic processes and has not been reported in PV. Laboratory findings included complete blood count (CBC) showed severe erythrocytosis, moderate leukocytosis with moderate, mild thrombocytosis; bone marrow (BM) aspiration and biopsy showed hypercellular BM and marked megakaryocytic hyperplasia; and positive JAK2V617F mutation with 80% JAK2 DNA, suggestive of PV as the underlying cause. The patient underwent phlebotomy and was started on Aspirin. Following treatment, she showed dramatic improvement in choreiform movements. Hydroxyurea 500 mg three times daily was subsequently added, leading to complete hematologic response and resolution of pachymeningeal thickening on follow up MRI. This case suggested association between polycythemia vera and choreiform movements and a possible mechanism is proposed.